Antidote’s proprietary treatments are targeting rare vascular diseases and addiction.
World-class experts, academic researchers, clinicians, and collaborating organizations
Antidote Therapeutics has established a global collaborative drug research and development network that leverages the depth of scientific expertise from leading academic laboratories in immunotherapeutic approaches for treating nicotine addiction, clinical research groups in vascular disease at leading hospitals, biotechnology companies, and consultants and advisors with decades of industrial biopharmaceutical drug development experience.
